Is Intellia Therapeutics Stock Halal?
How much of Intellia Therapeutics’ revenue comes from haram?
Intellia currently does not generate revenue from its therapeutic products, although it has many treatments in development for liver disorders, leukemia, and immuno-oncological disorders.
Intellia earns all of its revenue from collaboration agreements and research with Novartis for the treatment of sickle cell disease, Regeneron Pharmaceuticals for the treatment of hemophilia A and hemophilia B, and Ospedale San Raffaele for T cell therapies.
Practical Islamic Finance concludes:
None of Intellia’s revenue comes from anything inherently haram.
Does Intellia rely on interest to operate?
According to the company’s annual report for the fiscal year ended December 31, 2020 (Numbers in thousands, U.S. dollars):
Interest Income: $2,352
Total Revenue: $57,994
Interest Expense: $0
Total Expenses: $194,577
Interest Income / Revenue: 4.06%
Interest Expense / Total Expense: 0%
Practical Islamic Finance concludes:
Riba is used but not relied upon in Intellia’s operations. As Intellia’s business matures, we expect its use of interest will decrease, considering there is nothing inherent to its business model that relies on the use of interest.
What is Intellia Therapeutics’ Environmental, Social, and Governance (ESG) impact?
Environment
No notable environmental highlights.
Social
Intellia offers its employees the opportunity to buy shares of Intellia at a 15% discount with a maximum of $25,000 worth of stock per year.
In addition, Intellia has a high Glassdoor rating of 4.0 out of 5.0 from current and previous employees compared to a 3.3 average for all other Glassdoor rated companies.
Governance
No notable governance highlights.
Practical Islamic Finance concludes:
Intellia has a net positive ESG impact.
Comfort Rating
From Intellia’s business, financial, and ESG reviews, Practical Islamic Finance rates Intellia stock as: